p38 MAPK (pT180/pY182) Mouse, Alexa Fluor 488, Clone: 36/P38 (PT180/PY182), BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 612594
Activation of the immune and inflammatory responses often involves the recognition of bacterial endotoxin (lipopolysaccharide or LPS). Binding of LPS by monocytes results in the production and release of proinflammatory cytokines, such as IL-1 and TNF. LPS-induced signaling cascades involve members of the Ser/Thr protein kinase family known as the Mitogen Activated Protein Kinases (MAPKs). MAPK signal transduction pathways mediate the effects of various extracellular stimuli on biological processes such as proliferation, differentiation, and death. The p38 MAPKs include p38α (MAPK14), β (MAPK11), γ (MAPK12), and δ (MAPK13). These Ser/Thr kinases are activated by dual phosphorylation on threonine (T) and tyrosine (Y) within the motif Thr-Gly-Tyr located in kinase subdomain VIII. Activation of p38 MAPK is mediated specifically by the MAP Kinase Kinases, MKK3, MKK4, and MKK6. This leads to the activation of multiple transcription factors (NF-κB, ATF-2, Elk-1, and CHOP) that induce expression of many different genes, including proinflammatory cytokine genes. Thus, p38 MAPKs are central kinases in multiple signal transduction pathways. The 36/p38 (pT180/pY182) monoclonal antibody recognizes the conserved dual phosphorylated site pT180/pY182 of p38α, β, γ, and δ.
Flow Cytometry, Intracellular Staining
|p38 MAPK (pT180/pY182)|
|MAPK14; p38 MAP kinase; p38 MAPK; RK; CSBP2|
|Phosphorylated Human p38 MAPK (pT180/pY182) Peptide|
|Human, Murine, Rat|
|Alexa Fluor 488|
|Aqueous buffered solution containing BSA and ≤0.09% sodium azide.|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok